The Conversation (0)
Marina Biotech acquired the DyrctAxess technology platform from Symplmed Pharmaceuticals.
Marina Biotech (OTCQB:MRNA) acquired the DyrctAxess technology platform from Symplmed Pharmaceuticals.
As quoted in the press release:
DyrctAxess™ offers enhanced efficiency, control and information to empower patients, physicians and manufacturers to help achieve optimal care. The secure, web-based, HIPAA-compliant platform provides:
- Direct fulfillment of physician prescriptions at a fixed cost to patients
- Easy prescription, tracking and refill management via mobile applications (iPhone and Android)
- Real-time monitoring and communications between patients and physicians
- Complete database capture of insurance reimbursement and transparency of co-pay and coverage positions
- Automatic patient reminders and refills
- Enhanced security with 128 bit SSL
Prestalia® will continue to be marketed using DyrctAxess™, which drove strong compliance and patient engagement when developed by Symplmed. Prestalia® is currently protected by two patents listed in the U.S. Food and Drug Administration’s (FDA) publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The two Prestalia patents (6696481 and 7846961) offer product exclusivity until 2029.
Click here to read the full press release.
Source: globenewswire.com